Safety and immunogenicity of inactivated COVID-19 vaccine and virus vector vaccine in Thai adults with previous infection: Clinical trial

Completed

• Conditions: Healthy but had been previously infected with COVID-19; safety, immunogenicity, inactivated, virus vector COVID-19, vaccine

• Registration Number: TCTR20210520004
• Lead Sponsor: The National Research Council of Thailand

Brief Summary

The anti-RBD IgG titer after vaccination in previously infected participants was significantly boosted. At 28 days after a single dose vaccination, the short and long interval group possessed anti-RBD IgG with 12.87 fold (1549 BAU/mL) and 73.79 fold (2258 BAU/mL) compared to baseline following AZD1222 vaccination. In comparison, the increase of anti-RBD IgG with 3.12 fold (235 BAU/mL) and 7.79 fold (257 BAU/mL) were observed in short and long interval groups after a single dose of CoronaVac vaccine.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-05-20
• Study Completion: 2021-08-13
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

1. Healthy individuals above 18 years of age
2. History of COVID-19 infection confirmed by RT-PCR, with no symptoms for at least 28 days
3. Not in immunosuppresive conditions

Exclusion Criteria

1. Having received any COVID-19 vaccinations
2. Are being treated, hospitalized or have symptoms of COVID-19

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Immunogenicity 1 month post vaccination Anti-Spike RBD IgG

Secondary Outcome Measures

Name	Time	Method
T cell response 1 month post vaccination IFN-gamma release after T cell stimuation